Binding Site Information of Target
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T35640 | Target Info | |||
| Target Name | Integrin alpha-L (ITGAL) | ||||
| Synonyms | Lymphocyte Function-associated Antigen-1; Leukocyte function-associated molecule 1 alpha chain; Leukocyte function associated molecule 1, alpha chain; Leukocyte adhesion glycoprotein LFA-1 alpha chain; LFA-1A; LFA-1; CD11a; CD11 antigen-like family member A | ||||
| Target Type | Successful Target | ||||
| Gene Name | ITGAL | ||||
| Biochemical Class | Integrin | ||||
| UniProt ID | |||||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| Ligand Name: Lovastatin | Ligand Info | |||||
| Structure Description | X-ray structure of Lfa-1 I domain in complex with Lovastatin collected at 273 K | PDB:7KC6 | ||||
| Method | X-ray diffraction | Resolution | 1.85 Å | Mutation | No | [1] |
| PDB Sequence |
GSGNVDLVFL
135 FDGSMSLQPD145 EFQKILDFMK155 DVMKKLSNTS165 YQFAAVQFST175 SYKTEFDFSD 185 YVKRKDPDAL195 LKHVKHMLLL205 TNTFGAINYV215 ATEVFREELG225 ARPDATKVLI 235 IITDGEATDS245 GNIDAAKDII255 RYIIGIGKHF265 QTKESQETLH275 KFASKPASEF 285 VKILDTFEKL295 KDLFTELQKK305 IYVI
|
|||||
|
|
VAL130
3.782
LEU132
2.339
PHE134
4.278
PHE153
2.403
VAL157
2.962
LEU161
3.638
TYR166
3.237
PHE168
4.841
THR231
4.814
VAL233
2.475
ILE235
2.318
|
|||||
| Click to View More Binding Site Information of This Target and Ligand Pair | ||||||
| Ligand Name: Isoflurane | Ligand Info | |||||
| Structure Description | Crystal structure of wild type LFA1 I domain complexed with isoflurane | PDB:3F78 | ||||
| Method | X-ray diffraction | Resolution | 1.60 Å | Mutation | Yes | [2] |
| PDB Sequence |
GNVDLVFLFD
137 GSMSLQPDEF147 QKILDFMKDV157 MKKLSNTSYQ167 FAAVQFSTSY177 KTEFDFSDYV 187 KWKDPDALLK197 HVKHMLLLTN207 TFGAINYVAT217 EVFREELGAR227 PDATKVLIII 237 TDGEATDSGN247 IDAAKDIIRY257 IIGIGKHFQT267 KESQETLHKF277 ASKPASEFVK 287 ILDTFEKLKD297 LFTELQKKIY307
|
|||||
|
|
||||||
| Ligand Name: LFA703 | Ligand Info | |||||
| Structure Description | X-ray structure of LFA-1 I-domain in complex with LFA703 at 2.2A resolution | PDB:1XDD | ||||
| Method | X-ray diffraction | Resolution | 2.20 Å | Mutation | No | [3] |
| PDB Sequence |
GNVDLVFLFD
137 GSMSLQPDEF147 QKILDFMKDV157 MKKLSNTSYQ167 FAAVQFSTSY177 KTEFDFSDYV 187 KWKDPDALLK197 HVKHMLLLTN207 TFGAINYVAT217 EVFREELGAR227 PDATKVLIII 237 TDGEATDSGN247 IDAAKDIIRY257 IIGIGKHFQT267 KESQETLHKF277 ASKPASEFVK 287 ILDTFEKLKD297 LFTELQKKIY307 VI
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .AAY or .AAY2 or .AAY3 or :3AAY;style chemicals stick;color identity;select .A:128 or .A:130 or .A:132 or .A:153 or .A:157 or .A:161 or .A:166 or .A:231 or .A:233 or .A:235 or .A:255 or .A:257 or .A:259 or .A:284 or .A:285 or .A:287 or .A:298 or .A:301 or .A:302 or .A:305 or .A:306; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
GLY128
3.695
VAL130
3.682
LEU132
3.530
PHE153
4.042
VAL157
4.066
LEU161
4.302
TYR166
3.542
THR231
3.836
VAL233
4.040
ILE235
3.332
ILE255
3.849
|
|||||
| Ligand Name: BMS-587101 | Ligand Info | |||||
| Structure Description | CD11a (LFA1) I-domain complexed with BMS-587101 aka 5-[(5S, 9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro [4.4]non-7-yl]methyl]-3-thiophenecarboxylicacid | PDB:2ICA | ||||
| Method | X-ray diffraction | Resolution | 1.56 Å | Mutation | No | [4] |
| PDB Sequence |
MNVDLVFLFD
137 GSMSLQPDEF147 QKILDFMKDV157 MKKLSNTSYQ167 FAAVQFSTSY177 KTEFDFSDYV 187 KRKDPDALLK197 HVKHMLLLTN207 TFGAINYVAT217 EVFREELGAR227 PDATKVLIII 237 TDGEATDSGN247 IDAAKDIIRY257 IIGIGKHFQT267 KESQETLHKF277 ASKPASEFVK 287 ILDTFEKLKD297 LFTELQKKI
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .2IC or .2IC2 or .2IC3 or :32IC;style chemicals stick;color identity;select .A:130 or .A:132 or .A:134 or .A:153 or .A:157 or .A:160 or .A:161 or .A:166 or .A:231 or .A:233 or .A:235 or .A:255 or .A:257 or .A:259 or .A:284 or .A:287 or .A:298 or .A:299 or .A:302 or .A:303 or .A:305 or .A:306; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
VAL130
4.650
LEU132
4.051
PHE134
3.996
PHE153
4.139
VAL157
3.759
LYS160
4.520
LEU161
3.795
TYR166
3.027
THR231
4.186
VAL233
3.668
ILE235
3.620
|
|||||
| Ligand Name: 1-Acetyl-4-(4-{4-[(2-ethoxyphenyl)thio]-3-nitrophenyl}pyridin-2-YL)piperazine | Ligand Info | |||||
| Structure Description | An allosteric inhibitor of LFA-1 bound to its I-domain | PDB:1RD4 | ||||
| Method | X-ray diffraction | Resolution | 2.40 Å | Mutation | No | [5] |
| PDB Sequence |
GNVDLVFLFD
137 GSMSLQPDEF147 QKILDFMKDV157 MKKLSNTSYQ167 FAAVQFSTSY177 KTEFDFSDYV 187 KRKDPDALLK197 HVKHMLLLTN207 TFGAINYVAT217 EVFREELGAR227 PDATKVLIII 237 TDGEATDSGN247 IDAAKDIIRY257 IIGIGKHFQT267 KESQETLHKF277 ASKPASEFVK 287 ILDTFEKLKD297 LFTELQKKIY307 VIEG
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .L08 or .L082 or .L083 or :3L08;style chemicals stick;color identity;select .A:130 or .A:132 or .A:134 or .A:153 or .A:157 or .A:161 or .A:166 or .A:231 or .A:233 or .A:235 or .A:255 or .A:257 or .A:258 or .A:259 or .A:284 or .A:285 or .A:286 or .A:287 or .A:298 or .A:301 or .A:302 or .A:305; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
VAL130
4.755
LEU132
3.948
PHE134
3.865
PHE153
3.143
VAL157
3.542
LEU161
4.422
TYR166
2.923
THR231
4.195
VAL233
3.318
ILE235
3.268
ILE255
3.600
|
|||||
| Ligand Name: (2r)-2-[3-Isobutyl-2,5-Dioxo-4-(Quinolin-3-Ylmethyl)-1,4-Diazepan-1-Yl]-N-Methyl-3-(2-Naphthyl)propanamide | Ligand Info | |||||
| Structure Description | X-ray structure of LFA-1 I-domain bound to a 1,4-diazepane-2,5-dione inhibitor at 1.8A resolution | PDB:1XUO | ||||
| Method | X-ray diffraction | Resolution | 1.80 Å | Mutation | No | [6] |
| PDB Sequence |
GNVDLVFLFD
137 GSMSLQPDEF147 QKILDFMKDV157 MKKLSNTSYQ167 FAAVQFSTSY177 KTEFDFSDYV 187 KWKDPDALLK197 HVKHMLLLTN207 TFGAINYVAT217 EVFREELGAR227 PDATKVLIII 237 TDGEATDSGN247 IDAAKDIIRY257 IIGIGKHFQT267 KESQETLHKF277 ASKPASEFVK 287 ILDTFEKLKD297 LFTELQKKIY307 V
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .LA1 or .LA12 or .LA13 or :3LA1;style chemicals stick;color identity;select .A:130 or .A:132 or .A:153 or .A:157 or .A:166 or .A:231 or .A:233 or .A:235 or .A:255 or .A:257 or .A:259 or .A:284 or .A:285 or .A:287 or .A:295 or .A:298 or .A:299 or .A:302 or .A:305 or .A:306 or .A:308; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
VAL130
3.784
LEU132
4.243
PHE153
3.698
VAL157
4.566
TYR166
2.903
THR231
4.113
VAL233
3.787
ILE235
3.909
ILE255
3.879
TYR257
3.457
ILE259
3.972
|
|||||
| Ligand Name: 4-(3-{4-[(3-Aminopropyl)carbamoyl]phenyl}-1h-Indazol-1-Yl)-N-Methylbenzamide | Ligand Info | |||||
| Structure Description | X-ray structure of lfa-1 i-domain in complex with ibe-667 at 1.8a resolution | PDB:4IXD | ||||
| Method | X-ray diffraction | Resolution | 1.80 Å | Mutation | No | [7] |
| PDB Sequence |
GNVDLVFLFD
137 GSMSLQPDEF147 QKILDFMKDV157 MKKLSNTSYQ167 FAAVQFSTSY177 KTEFDFSDYV 187 KWKDPDALLK197 HVKHMLLLTN207 TFGAINYVAT217 EVFREELGAR227 PDATKVLIII 237 TDGEATDSGN247 IDAAKDIIRY257 IIGIGKHFQT267 KESQETLHKF277 ASKPASEFVK 287 ILDTFEKLKD297 LFTELQKKIY307 VI
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .1HV or .1HV2 or .1HV3 or :31HV;style chemicals stick;color identity;select .A:130 or .A:132 or .A:153 or .A:166 or .A:231 or .A:233 or .A:235 or .A:255 or .A:257 or .A:259 or .A:287 or .A:298 or .A:301 or .A:302 or .A:305; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| Ligand Name: (1S,3R,8AS)-8-(2-{(4S,6S)-3-(4-Hydroxy-3-methoxybenzyl)-4-[2-(methylamino)-2-oxoethyl]-2-oxo-1,3-oxazinan-6-YL}ethyl)-3,7-dimethyl-1,2,3,7,8,8A-hexahydronaphthalen-1-YL (2R)-2-methylbutanoate | Ligand Info | |||||
| Structure Description | X-ray structure of LFA-1 I-domain in complex with LFA878 at 2.1A resolution | PDB:1XDG | ||||
| Method | X-ray diffraction | Resolution | 2.10 Å | Mutation | No | [3] |
| PDB Sequence |
GNVDLVFLFD
137 GSMSLQPDEF147 QKILDFMKDV157 MKKLSNTSYQ167 FAAVQFSTSY177 KTEFDFSDYV 187 KWKDPDALLK197 HVKHMLLLTN207 TFGAINYVAT217 EVFREELGAR227 PDATKVLIII 237 TDGEATDSGN247 IDAAKDIIRY257 IIGIGKHFQT267 KESQETLHKF277 ASKPASEFVK 287 ILDTFEKLKD297 LFTELQKKIY307 VI
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .AB8 or .AB82 or .AB83 or :3AB8;style chemicals stick;color identity;select .A:130 or .A:132 or .A:153 or .A:157 or .A:161 or .A:166 or .A:233 or .A:235 or .A:255 or .A:257 or .A:259 or .A:284 or .A:285 or .A:287 or .A:298 or .A:301 or .A:302 or .A:305 or .A:309; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| Ligand Name: Cis-4-{[2-({4-[(1e)-3-Morpholin-4-Yl-3-Oxoprop-1-En-1-Yl]-2,3-Bis(Trifluoromethyl)phenyl}sulfanyl)phenoxy]methyl}cyclohexanecarboxylic Acid | Ligand Info | |||||
| Structure Description | LFA-1 I domain bound to inhibitors | PDB:3E2M | ||||
| Method | X-ray diffraction | Resolution | 2.00 Å | Mutation | Yes | [8] |
| PDB Sequence |
GNVDLVFLFD
137 GSMSLQPDEF147 QKILDFMKDV157 MKKLSNTSYQ167 FAAVQFSTSY177 KTEFDFSDYV 187 KWKDPDALLK197 HVKHMLLLTN207 TFGAINYVAT217 EVFREELGAR227 PDATKVLIII 237 TDGEATDSGN247 IDAAKDIIRY257 IIGIGKHFQT267 KESQETLHKF277 ASKPASEFVK 287 ILDTFEKLKD297 LFTELQKKIY307 VI
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .E2M or .E2M2 or .E2M3 or :3E2M;style chemicals stick;color identity;select .A:130 or .A:132 or .A:134 or .A:153 or .A:157 or .A:161 or .A:166 or .A:231 or .A:233 or .A:235 or .A:255 or .A:257 or .A:258 or .A:259 or .A:284 or .A:285 or .A:286 or .A:287 or .A:298 or .A:301 or .A:302 or .A:305; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
VAL130
4.264
LEU132
3.142
PHE134
3.912
PHE153
3.507
VAL157
3.119
LEU161
4.105
TYR166
2.562
THR231
4.625
VAL233
4.428
ILE235
3.727
ILE255
4.037
|
|||||
| Ligand Name: 7a-[(4-Cyanophenyl)methyl]-6-(3,5-Dichlorophenyl)-5-Oxo-2,3,5,7a-Tetrahydro-1h-Pyrrolo[1,2-A]pyrrole-7-Carbonitrile | Ligand Info | |||||
| Structure Description | CD11A (LFA1) I-domain complexed with 7A-[(4-cyanophenyl)methyl]-6-(3,5-dichlorophenyl)-5-oxo-2,3,5,7A-tetrahydro-1H-pyrrolo[1,2-A]pyrrole-7-carbonitrile | PDB:2O7N | ||||
| Method | X-ray diffraction | Resolution | 1.75 Å | Mutation | No | [9] |
| PDB Sequence |
MNVDLVFLFD
137 GSMSLQPDEF147 QKILDFMKDV157 MKKLSNTSYQ167 FAAVQFSTSY177 KTEFDFSDYV 187 KRKDPDALLK197 HVKHMLLLTN207 TFGAINYVAT217 EVFREELGAR227 PDATKVLIII 237 TDGEATDSGN247 IDAAKDIIRY257 IIGIGKHFQT267 KESQETLHKF277 ASKPASEFVK 287 ILDTFEKLKD297 LFTELQKKIY307
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .2O7 or .2O72 or .2O73 or :32O7;style chemicals stick;color identity;select .A:128 or .A:130 or .A:132 or .A:134 or .A:153 or .A:157 or .A:160 or .A:161 or .A:166 or .A:233 or .A:235 or .A:257 or .A:259 or .A:284 or .A:287 or .A:298 or .A:302 or .A:303 or .A:305 or .A:306; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
MET128
4.730
VAL130
4.429
LEU132
3.326
PHE134
3.862
PHE153
4.266
VAL157
3.730
LYS160
4.623
LEU161
4.014
TYR166
2.786
VAL233
3.997
|
|||||
| Ligand Name: 6-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]pyridine-3-carboxylic acid | Ligand Info | |||||
| Structure Description | CD11A I-domain complexed with 6-((5S,9R)-9-(4-CYANOPHENYL)-3-(3,5-DICHLOROPHENYL)-1-METHYL-2,4-DIOXO-1,3,7- TRIAZASPIRO[4.4]NON-7-YL)NICOTINIC ACID | PDB:3M6F | ||||
| Method | X-ray diffraction | Resolution | 1.85 Å | Mutation | No | [10] |
| PDB Sequence |
MNVDLVFLFD
137 GSMSLQPDEF147 QKILDFMKDV157 MKKLSNTSYQ167 FAAVQFSTSY177 KTEFDFSDYV 187 KRKDPDALLK197 HVKHMLLLTN207 TFGAINYVAT217 EVFREELGAR227 PDATKVLIII 237 TDGEATDSGN247 IDAAKDIIRY257 IIGIGKHFQT267 KESQETLHKF277 ASKPASEFVK 287 ILDTFEKLKD297 LFTELQKKIY307
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .BJZ or .BJZ2 or .BJZ3 or :3BJZ;style chemicals stick;color identity;select .A:130 or .A:132 or .A:134 or .A:153 or .A:157 or .A:160 or .A:161 or .A:166 or .A:231 or .A:233 or .A:235 or .A:255 or .A:257 or .A:259 or .A:284 or .A:287 or .A:298 or .A:299 or .A:302 or .A:303 or .A:305 or .A:306; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
VAL130
3.880
LEU132
4.199
PHE134
3.952
PHE153
4.204
VAL157
3.765
LYS160
4.756
LEU161
3.893
TYR166
3.040
THR231
2.702
VAL233
3.809
ILE235
3.577
|
|||||
| Click to View More Binding Site Information of This Target and Ligand Pair | ||||||
| Ligand Name: 4-{(2e)-3-[4-{[2-(Pyridin-3-Ylmethoxy)phenyl]sulfanyl}-2,3-Bis(Trifluoromethyl)phenyl]prop-2-Enoyl}morpholine | Ligand Info | |||||
| Structure Description | LFA-1 I domain bound to inhibitors | PDB:3BQN | ||||
| Method | X-ray diffraction | Resolution | 1.80 Å | Mutation | Yes | [8] |
| PDB Sequence |
GNVDLVFLFD
137 GSMSLQPDEF147 QKILDFMKDV157 MKKLSNTSYQ167 FAAVQFSTSY177 KTEFDFSDYV 187 KWKDPDALLK197 HVKHMLLLTN207 TFGAINYVAT217 EVFREELGAR227 PDATKVLIII 237 TDGEATDSGN247 IDAAKDIIRY257 IIGIGKHFQT267 KESQETLHKF277 ASKPASEFVK 287 ILDTFEKLKD297 LFTELQKKIY307 VI
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .BQN or .BQN2 or .BQN3 or :3BQN;style chemicals stick;color identity;select .B:130 or .B:132 or .B:134 or .B:153 or .B:157 or .B:161 or .B:166 or .B:231 or .B:233 or .B:235 or .B:255 or .B:257 or .B:258 or .B:259 or .B:284 or .B:285 or .B:286 or .B:287 or .B:298 or .B:301 or .B:302 or .B:305; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
VAL130
4.389
LEU132
3.040
PHE134
3.713
PHE153
3.370
VAL157
3.206
LEU161
3.963
TYR166
2.563
THR231
4.547
VAL233
4.169
ILE235
3.546
ILE255
3.801
|
|||||
| Ligand Name: 3-({4-[(1E)-3-morpholin-4-yl-3-oxoprop-1-en-1-yl]-2,3-bis(trifluoromethyl)phenyl}sulfanyl)aniline | Ligand Info | |||||
| Structure Description | LFA-1 I domain bound to inhibitors | PDB:3BQM | ||||
| Method | X-ray diffraction | Resolution | 1.95 Å | Mutation | Yes | [11] |
| PDB Sequence |
GNVDLVFLFD
137 GSMSLQPDEF147 QKILDFMKDV157 MKKLSNTSYQ167 FAAVQFSTSY177 KTEFDFSDYV 187 KWKDPDALLK197 HVKHMLLLTN207 TFGAINYVAT217 EVFREELGAR227 PDATKVLIII 237 TDGEATDSGN247 IDAAKDIIRY257 IIGIGKHFQT267 KESQETLHKF277 ASKPASEFVK 287 ILDTFEKLKD297 LFTELQKKIY307 VI
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .BQM or .BQM2 or .BQM3 or :3BQM;style chemicals stick;color identity;select .B:130 or .B:132 or .B:134 or .B:153 or .B:157 or .B:161 or .B:166 or .B:231 or .B:233 or .B:235 or .B:255 or .B:257 or .B:258 or .B:259 or .B:284 or .B:285 or .B:286 or .B:287 or .B:298 or .B:302; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
VAL130
4.405
LEU132
3.209
PHE134
4.027
PHE153
3.356
VAL157
3.289
LEU161
4.049
TYR166
2.787
THR231
4.290
VAL233
3.960
ILE235
3.665
|
|||||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Divergent conformational dynamics controls allosteric ligand accessibility across evolutionarily related I-domain-containing integrins | ||||
| REF 2 | Crystal structure of isoflurane bound to integrin LFA-1 supports a unified mechanism of volatile anesthetic action in the immune and central nervous systems. FASEB J. 2009 Aug;23(8):2735-40. | ||||
| REF 3 | Improved lymphocyte function-associated antigen-1 (LFA-1) inhibition by statin derivatives: molecular basis determined by x-ray analysis and monitoring of LFA-1 conformational changes in vitro and ex vivo. J Biol Chem. 2004 Nov 5;279(45):46764-71. | ||||
| REF 4 | Discovery and development of 5-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl-methyl]-3-thioph... J Med Chem. 2006 Nov 30;49(24):6946-9. | ||||
| REF 5 | Structure of an allosteric inhibitor of LFA-1 bound to the I-domain studied by crystallography, NMR, and calorimetry. Biochemistry. 2004 Mar 9;43(9):2394-404. | ||||
| REF 6 | 1,4-Diazepane-2,5-diones as novel inhibitors of LFA-1. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1217-20. | ||||
| REF 7 | Identification and x-ray structure based investigation of an ICAM-1 binding enhancing small molecule activator of LFA-1 | ||||
| REF 8 | Structure-activity relationship of ortho- and meta-phenol based LFA-1 ICAM inhibitors. Bioorg Med Chem Lett. 2008 Oct 1;18(19):5245-8. | ||||
| REF 9 | Design of LFA-1 antagonists based on a 2,3-dihydro-1H-pyrrolizin-5(7aH)-one scaffold. Bioorg Med Chem Lett. 2007 Apr 1;17(7):1908-11. | ||||
| REF 10 | Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1): structure-activity relationships leading to the identification of 6-(... J Med Chem. 2010 May 13;53(9):3814-30. | ||||
| REF 11 | Design and synthesis of a series of meta aniline-based LFA-1 ICAM inhibitors. Bioorg Med Chem Lett. 2008 Oct 1;18(19):5249-51. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.